Mr. Dwight Gorham reports

INTELGENX RECEIVES AMENDED DEL LICENSE TO CONDUCT THIRD-PARTY TESTING

IntelGenx Corp. has received an amended drug establishment licence (DEL) from Health Canada, allowing the company to conduct third party testing.

Analytical testing of finished products and intermediates is a significantly underserved market, which IntelGenx has decided to tap into. The company views this as an attractive opportunity for short-term revenue generation. The amended DEL licence could be of particular importance due to IntelGenx's possession of a controlled substance licence. This allows IntelGenx to access a broader market for testing services, further increasing its market penetration and revenue opportunities.

"By expanding our core CDMO business to include a third party testing services offering, our aim is to offer one-stop shopping to our development partners," said Dwight Gorham, IntelGenx's chief executive officer. "IntelGenx's testing laboratory boasts exceptional efficiency and is currently operating at under capacity. This surplus in capacity allows us to seize the opportunity to generate revenue from third party testing without any additional investment. While testing services will not be our primary focus, the added revenue will be welcomed, while at the same time, help foster business relationships with key players in the Canadian market."

About IntelGenx Corp.

IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films.

IntelGenx's superior film technologies, including VersaFilm, DisinteQ, VetaFilm and transdermal VevaDerm, allow for next-generation pharmaceutical products that address unmet medical needs. IntelGenx's innovative product pipeline offers significant benefits to patients and physicians for many therapeutic conditions.

We seek Safe Harbor.